This trial is testing a new cancer drug, DCC-3014, in patients with solid tumors or a rare tumor of the tendon called tenosynovial giant cell tumor (TGCT). The trial has two parts: dose escalation (phase 1) and expansion (phase 2). In phase 1, both types of patients will be enrolled. In phase 2, only TGCT patients will be enrolled, in two different cohorts.
- Giant Cell Tumor of the Tendon Sheath
- Diffuse Tenosynovial Giant Cell Tumor
- Pigmented Villonodular Synovitis
- Giant Cell Tumor of Tendon Sheath
9 Primary · 5 Secondary · Reporting Duration: Cycle 1 through study completion (~ 24 months)
0 Treatment Group
120 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment for this research endeavor still being accepted?
"The clinical trial's introduction and latest update can both be found on the website of clinicaltrials.gov. This research was published in February 2017, with an updated version issued December 2021. The project is currently seeking participants to join its ranks." - Anonymous Online Contributor
At how many centers is this experiment taking place?
"This medical trial is currently enrolling patients at numerous research centers, such as Stanford Cancer Institute in Palo Alto, California; MSKCC in New York City; and Oregon Health & Science University situated in Portland, Oregon." - Anonymous Online Contributor
What is the scope of enrollment for this clinical trial?
"This trial requires 120 volunteers who meet the eligibility criteria. Participatory locations include Stanford Cancer Institute in Palo Alto and MSKCC, located in New York City." - Anonymous Online Contributor
What is the fundamental purpose behind this clinical experiment?
"According to Deciphera Pharmaceuticals LLC., the primary measure of efficacy over a 24-month period is Maximum tolerated dose. Additionally, Response rate (Expansion Phase only) assessed by central read using tumor volume score and modified RECIST (mRECIST) Version 1.1, Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function Score (Expansion Phase only), and Worst Stiffness Numeric Rating Scale (NRS) Score(Expansion Phase only) are being studied as secondary outcomes." - Anonymous Online Contributor